NEW YORK (GenomeWeb News) – Shares of Sequenom rose 17.6 percent to close at $5.95 in Thursday trade on the Nasdaq after Cantor Fitzgerald initiated coverage of the firm with a “buy” rating.
Cantor Fitzgerald also placed a $12 price target on Sequenom’s shares and expects the firm to become profitable in 2010. The Cantor Fitzgerald analyst cited the revenue growth potential of Sequenom’s MassArray system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.